Biogen | BIIB - Debt


Biogen reported $8.09B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Sanofi EUR 20.02B 1.73B Mar/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026